|
|
| Countries covered: United States Intellent's new industry report focuses on the US type 2 diabetes market. This report provides valuable insight and access to the competitive information and analysis necessary to make decisions regarding the direction of the market from 2009 -2013. This primary research report features information and analysis that can't be found anywhere else. Our report features information gathered from pharmaceutical, payer, and key opinion leader interviews. This report reveals what changes lay ahead for the diabetes market in the US. It evaluates current drugs and makes projections on drugs poised to influence the future market. Diabetes is one of the most common diseases in the United States, affecting more than 24 million people. It is a metabolic disorder mainly caused by a defect in insulin production or absorption, resulting in a high level of blood glucose or blood sugar. A person having blood glucose level HbA1c of greater than seven is considered to be diabetic. It is estimated that approximately 90 to 95 percent of diabetics are type 2 diabetics and can be treated by oral anti-diabetics or with a combination of injectable insulin and anti-diabetic drugs. In 2008, the US anti-diabetic market was estimated to be worth $11.5 billion. The market is forecasted to grow at a cumulative annual growth rate (CAGR) of 6.4 percent over the forecast period. By the end of the forecast period, 2013, the market is estimated to generate $15.7 billion in revenues. Our Intellent diabetes report provides detailed analyses into the potential growth in revenue from the new DPP-IVs and GLP-1s. The report also delivers information on which segments are poised to grow the most over our forecast period as some of the biggest selling drugs lose patent protection. We provide exclusive payer opinions on how effective the current anti-diabetic armamentarium is and what managed care sees as keys to the future. Intellent utilizes our deep expertise in the field of diabetes to provide an accurate and detailed SWOT analysis of some of the most promising agents about to come to market, such as liraglutide, exenatide LAR, saxagliptin, dapagliflozin, and many more. Intellent also provides detailed pipeline analysis about which companies are developing the most anti-diabetics and where they are in development. Our report breaks down the therapeutic area as a whole, in order to show readers which companies are the most heavily invested. Intellent also provides an up-to the minute picture of both early and late phase drugs. |
More United States Diabetes Reports
Insulin - Top 5 American Markets by
Global Research & Data Services
This market research report package offers an in-depth perspective on the actual market situation, trends and future outlook for insulin in top 5 American markets. ...
Insulin - Americas by
Global Research & Data Services
This market research report package offers an in-depth perspective on the actual market situation, trends and future outlook for insulin in American markets. The analyses ...
Insulin - United States by
Global Research & Data Services
This market research report offers a perspective on the actual market situation, trends and future outlook for insulin in United States. The study provides essential ...
Targeted Health and Wellness Foods and Beverages: The U.S. Market and Global Trends by
Packaged Facts
The market for targeted health and wellness foods and beverages is a dynamic and promising one, driven largely by the growing recognition—among scientists, government, practitioners, ...
US Glucose Monitoring Market Analysis by
RNCOS
The US has a dominant share in the global diabetes market with 90-95% of the diabetic patients in the country suffering from type-II diabetes. Factors ...
See all reports like this >>
More United States Reports
e-Discovery Software Publishing in the US - Industry Market Research Report by
IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...
D&B Country RiskLine Report: The United States of America by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by
Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>
